title: Anticancer drug-incorporated layered double hydroxide nanohybrids and their enhanced anticancer therapeutic efficacy in combination cancer treatment.
abstract: OBJECTIVE
  Layered double hydroxide (LDH) nanoparticles have been studied as cellular delivery carriers for anionic anticancer agents. As MTX and 5-FU are clinically utilized anticancer drugs in combination therapy, we aimed to enhance the therapeutic performance with the help of LDH nanoparticles.
  
  
  METHODS
  Anticancer drugs, MTX and 5-FU, and their combination, were incorporated into LDH by reconstruction method. Simply, LDHs were thermally pretreated at 400°C, and then reacted with drug solution to simultaneously form drug-incorporated LDH. Thus prepared MTX/LDH (ML), 5-FU/LDH (FL), and (MTX + 5-FU)/LDH (MFL) nanohybrids were characterized by X-ray diffractometer, scanning electron microscopy, infrared spectroscopy, thermal analysis, zeta potential measurement, dynamic light scattering, and so forth. The nanohybrids were administrated to the human cervical adenocarcinoma, HeLa cells, in concentration-dependent manner, comparing with drug itself to verify the enhanced therapeutic efficacy.
  
  
  CONCLUSIONS
  All the nanohybrids successfully accommodated intended drug molecules in their house-of-card-like structures during reconstruction reaction. It was found that the anticancer efficacy of MFL nanohybrid was higher than other nanohybrids, free drugs, or their mixtures, which means the multidrug-incorporated LDH nanohybrids could be potential drug delivery carriers for efficient cancer treatment via combination therapy.
authors.affiliation: Department of Chemistry & Medical Chemistry, College of Science & Technology, Yonsei University, Wonju, Gangwon-do 220-710, Republic of Korea.
authors.forename: Tae-Hyun
authors.identifier: 0000-0002-4777-1182
authors.initials: TH
authors.lastname: Kim
authors.affiliation: Department of Biosystems and Biomaterials Science and Engineering, College of Agriculture and Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea.
authors.forename: Gyeong Jin
authors.initials: GJ
authors.lastname: Lee
authors.affiliation: Ewha-Solvay Research & Innovation Center, 150 Bukahyun-ro, Seodaemun-gu, Seoul 120-140, Republic of Korea.
authors.forename: Joo-Hee
authors.initials: JH
authors.lastname: Kang
authors.affiliation: Department of Chemistry & Medical Chemistry, College of Science & Technology, Yonsei University, Wonju, Gangwon-do 220-710, Republic of Korea.
authors.forename: Hyoung-Jun
authors.identifier: 0000-0003-0101-3172
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: Department of Biosystems and Biomaterials Science and Engineering, College of Agriculture and Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea.
authors.forename: Tae-Il
authors.identifier: 0000-0002-9355-7574
authors.initials: TI
authors.lastname: Kim
authors.affiliation: Department of Chemistry & Medical Chemistry, College of Science & Technology, Yonsei University, Wonju, Gangwon-do 220-710, Republic of Korea.
authors.forename: Jae-Min
authors.identifier: 0000-0003-1638-9957
authors.initials: JM
authors.lastname: Oh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000737:chemistry*; D017209:Apoptosis / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects*; D004058:Diffusion; D004357:Drug Synergism; D005472:Fluorouracil / Q000008:administration & dosage / Q000737:chemistry; D006367:HeLa Cells; D006801:Humans; D006878:Hydroxides / Q000737:chemistry; D008727:Methotrexate / Q000008:administration & dosage / Q000737:chemistry; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry*; D058726:Nanoconjugates / Q000008:administration & dosage / Q000737:chemistry*
chemical_list: D006878:Hydroxides; D053769:Nanocapsules; D058726:Nanoconjugates; D005472:Fluorouracil; D008727:Methotrexate